相关实验视频
Updated: Jul 11, 2025

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
2.1K
在正确的审查下重新审视发生率的比较
Pablo Martínez-Camblor1,2, Susana Díaz-Coto3
1Department of Anesthesiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
The international journal of biostatistics
|November 13, 2023
概括
这项研究澄清了在权利审查下发生率估计,这是生存分析中的一个常见挑战. 我们分析了审查如何影响结果,并提出了提高发病率比较准确性的方法.
科学领域:
- 生物统计学 生物统计学
- 流行病学 流行病学
- 生存分析的分析.
背景情况:
- 数据描述对于了解问题至关重要,但像发病率这样的描述性指标可能会被误解.
- 发病率,定义为事件除以人处于危险的时间,呈现解释的复杂性,特别是在审查数据.
研究的目的:
- 在存在权利审查的情况下,重新审视发生率估计.
- 分析审查时间分布对观察结果和发病率比较的影响.
- 提出一种方法来减轻数据收集过程对假设测试的影响.
主要方法:
- 在正确的审查下,修订发病率估计器.
- 分析审查时间分配的影响.
- 蒙特卡洛模拟用于探索估计者的有限样本行为.
- 使用合成数据的说明性示例.
主要成果:
- 审查时间分布显著影响观察到的发病率及其比较.
- 提出的解决方案可以限制数据收集对假设测试结果的影响.
- 蒙特卡洛模拟为估计者的有限样本行为提供了洞察力.
结论:
- 准确解释发病率需要仔细考虑权利审查.
- 提出的方法提高了发病率估计和生存数据比较的可靠性.
- 了解审查效应对于强大的流行病学和生物统计学分析至关重要.
相关概念视频
Censoring Survival Data
108
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
108
Prevalence and Incidence
579
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
579
Comparing the Survival Analysis of Two or More Groups
200
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
200
Relative Risk
191
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
191
Hazard Rate
115
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
115
Hazard Ratio
136
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
136

